Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C] AZ12713580 is a radiolabeled small molecule used as a positron emission tomography (PET) imaging agent to measure central metabotropic glutamate receptor 5 (mGluR5) occupancy in the brain. It is primarily utilized in clinical research to assess the binding and pharmacodynamics of investigational drugs targeting mGluR5, such as AZD2066 and AZD2516, by quantifying receptor occupancy after administration of these compounds in healthy subjects. The compound contains carbon-11 ([11C]), a positron-emitting radioisotope, enabling visualization and quantification of its distribution via PET scanning. Its mechanism involves selective binding to mGluR5 receptors, allowing for non-invasive assessment of target engagement in the central nervous system[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C] AZ12713580.